IP Library Granted Patent US 7,442,782
Granted Patent B2
US 7,442,782 · App. 10/890,685 · Granted Oct 28, 2008

Intron associated with myotonic dystrophy type 2 and methods of use

Assignee: Regents of the University of Minnesota
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,442,782
App. No.
10/890,685
Granted
Oct 28, 2008
Kind
B2
Abstract

The present invention provides methods for identifying individuals not at risk for developing myotonic dystrophy type 2 (DM2), and individuals that have or at risk for developing DM2. The present invention also provides isolated polynucleotides that include a repeat tract within intron 1 of the zinc finger protein 9.

Claims (10)

1. An isolated polynucleotide comprising about nucleotides 17501-17701 of SEQ ID NO:1 and an at risk repeat tract, and the full complements thereof.

2. An isolated polynucleotide comprising about nucleotides 17858-18062 of SEQ ID NO:1 and an at risk repeat tract, and the full complements thereof.

3. The isolated polynucleotide of claim 1 wherein the at risk repeat tract comprises (TG) x (TCTG) y (CCTG) z ,

wherein x is an integer from 14 to 25, y is an integer from 3 to 10, and z is an integer from 75 to 11,000.

4. The isolated polynucleotide of claim 1 wherein the at risk repeat tract comprises from 75 to 11,000 CCTG repeats.

5. The isolated polynucleotide of claim 4 wherein the at risk repeat tract comprises at least 75 CCTG repeats uninterrupted by other nucleotides.

6. The isolated polynucleotide of claim 2 wherein the at risk repeat tract comprises (TG) x (TCTG) y (CCTG) z ,

wherein x is an integer from 14 to 25, y is an integer from 3 to 10, and z is an integer from 75 to 11,000.

7. The isolated polynucleotide of claim 2 wherein the at risk repeat tract comprises from 75 to 11,000 CCTG repeats.

8. The isolated polynucleotide of claim 7 wherein the at risk repeat tract comprises at least 75 CCTG repeats uninterrupted by other nucleotides.

Continuity (5)
Division 1014326600 · May 10, 2002
Provisional Application 6033783100 · Nov 13, 2001
Provisional Application 6030202200 · Jun 29, 2001
Provisional Application 6029036500 · May 11, 2001
Related Publication 20050003426A1 · Jan 6, 2005